Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
- PMID: 32007141
- PMCID: PMC7043009
- DOI: 10.1016/S0140-6736(20)30068-4
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
Abstract
Background: The WHO Director-General has issued a call for action to eliminate cervical cancer as a public health problem. To help inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical screening scenarios in low-income and lower-middle-income countries (LMICs) to examine the feasibility and timing of elimination at different thresholds, and to estimate the number of cervical cancer cases averted on the path to elimination.
Methods: The WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), which consists of three independent transmission-dynamic models identified by WHO according to predefined criteria, projected reductions in cervical cancer incidence over time in 78 LMICs for three standardised base-case scenarios: girls-only vaccination; girls-only vaccination and once-lifetime screening; and girls-only vaccination and twice-lifetime screening. Girls were vaccinated at age 9 years (with a catch-up to age 14 years), assuming 90% coverage and 100% lifetime protection against HPV types 16, 18, 31, 33, 45, 52, and 58. Cervical screening involved HPV testing once or twice per lifetime at ages 35 years and 45 years, with uptake increasing from 45% (2023) to 90% (2045 onwards). The elimination thresholds examined were an average age-standardised cervical cancer incidence of four or fewer cases per 100 000 women-years and ten or fewer cases per 100 000 women-years, and an 85% or greater reduction in incidence. Sensitivity analyses were done, varying vaccination and screening strategies and assumptions. We summarised results using the median (range) of model predictions.
Findings: Girls-only HPV vaccination was predicted to reduce the median age-standardised cervical cancer incidence in LMICs from 19·8 (range 19·4-19·8) to 2·1 (2·0-2·6) cases per 100 000 women-years over the next century (89·4% [86·2-90·1] reduction), and to avert 61·0 million (60·5-63·0) cases during this period. Adding twice-lifetime screening reduced the incidence to 0·7 (0·6-1·6) cases per 100 000 women-years (96·7% [91·3-96·7] reduction) and averted an extra 12·1 million (9·5-13·7) cases. Girls-only vaccination was predicted to result in elimination in 60% (58-65) of LMICs based on the threshold of four or fewer cases per 100 000 women-years, in 99% (89-100) of LMICs based on the threshold of ten or fewer cases per 100 000 women-years, and in 87% (37-99) of LMICs based on the 85% or greater reduction threshold. When adding twice-lifetime screening, 100% (71-100) of LMICs reached elimination for all three thresholds. In regions in which all countries can achieve cervical cancer elimination with girls-only vaccination, elimination could occur between 2059 and 2102, depending on the threshold and region. Introducing twice-lifetime screening accelerated elimination by 11-31 years. Long-term vaccine protection was required for elimination.
Interpretation: Predictions were consistent across our three models and suggest that high HPV vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden.
Funding: WHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Special Program of Research, Development and Research Training in Human Reproduction, Canadian Institute of Health Research, Fonds de recherche du Québec-Santé, Compute Canada, National Health and Medical Research Council Australia Centre for Research Excellence in Cervical Cancer Control.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Figures
Comment in
-
Eliminating cervical cancer.Lancet. 2020 Feb 1;395(10221):312. doi: 10.1016/S0140-6736(20)30247-6. Lancet. 2020. PMID: 32007146 No abstract available.
Similar articles
-
Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.Lancet. 2020 Feb 22;395(10224):591-603. doi: 10.1016/S0140-6736(20)30157-4. Epub 2020 Jan 30. Lancet. 2020. PMID: 32007142 Free PMC article.
-
Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.Lancet Oncol. 2019 Mar;20(3):394-407. doi: 10.1016/S1470-2045(18)30836-2. Epub 2019 Feb 19. Lancet Oncol. 2019. PMID: 30795950
-
Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.Lancet Infect Dis. 2021 Nov;21(11):1598-1610. doi: 10.1016/S1473-3099(20)30860-4. Epub 2021 Jul 7. Lancet Infect Dis. 2021. PMID: 34245682 Free PMC article.
-
Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.Lancet Public Health. 2016 Nov;1(1):e8-e17. doi: 10.1016/S2468-2667(16)30001-9. Epub 2016 Sep 27. Lancet Public Health. 2016. PMID: 29253379 Free PMC article. Review.
-
The next steps in cervical screening.Womens Health (Lond). 2015 Mar;11(2):201-12. doi: 10.2217/whe.14.70. Womens Health (Lond). 2015. PMID: 25776294 Review.
Cited by
-
Effects of screening coverage and screening quality assurance on cervical cancer mortality: Implication for integrated framework to monitor global implementation of cervical cancer screening programmes.J Glob Health. 2024 Oct 25;14:04189. doi: 10.7189/jogh.14.04189. J Glob Health. 2024. PMID: 39450607 Free PMC article.
-
Enhancing insights into Global Cancer Statistics 2022: implications for cancer control.Sci China Life Sci. 2024 Oct 18. doi: 10.1007/s11427-024-2734-6. Online ahead of print. Sci China Life Sci. 2024. PMID: 39432206 No abstract available.
-
Prevalence of Human Papillomavirus (HPV) Infection and its Association With Pap Smear Findings Among Women Attending a Gynecology Clinic in Khorasan Razavi-Iran.J Res Health Sci. 2024 Sep 30;24(4):e00629. doi: 10.34172/jrhs.2024.164. Epub 2024 Sep 30. J Res Health Sci. 2024. PMID: 39431654 Free PMC article.
-
Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer.Ecancermedicalscience. 2024 Sep 11;18:1762. doi: 10.3332/ecancer.2024.1762. eCollection 2024. Ecancermedicalscience. 2024. PMID: 39430092 Free PMC article. Review.
-
'Addressing HPV vaccine hesitancy: unveiling concerns and building trust' perspectives of adolescent girls and parents in Kisumu County, Kenya.Ecancermedicalscience. 2024 Aug 5;18:1735. doi: 10.3332/ecancer.2024.1735. eCollection 2024. Ecancermedicalscience. 2024. PMID: 39421184 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
-
- PATH Global HPV Vaccine Introduction Overview: projected and current national introductions, demonstration/pilot projects, gender-neutral vaccination programs, and global HPV vaccine introduction maps (2006–2022) November, 2019. https://www.path.org/resources/global-hpv-vaccine-introduction-overview/
-
- WHO Immunization, vaccines and biologicals: data, statistics and graphics. https://www.who.int/immunization/monitoring_surveillance/data/en/
-
- Riley L. Monitoring cervical cancer: screening and treatment coverage. Presentation using the WHO Steps Survey (cervical cancer screening) 2019. https://apps.who.int/iris/handle/10665/275391